This “Ischemia Reperfusion Injury - Pipeline Insight, 2021” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Ischemia Reperfusion Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ischaemia-Reperfusion injury (IRI) is defined as the paradoxical exacerbation of cellular dysfunction and death, following restoration of blood flow to previously ischaemic tissues. Reestablishment of blood flow is essential to salvage ischaemic tissues. However reperfusion itself paradoxically causes further damage, threatening function and viability of the organ. IRI occurs in a wide range of organs including the heart, lung, kidney, gut, skeletal muscle and brain and may involve not only the ischaemic organ itself but may also induce systemic damage to distant organs, potentially leading to multi-system organ failure. Reperfusion injury is a multi-factorial process resulting in extensive tissue destruction.
"Ischemia Reperfusion Injury - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ischemia Reperfusion Injury pipeline landscape is provided which includes the disease overview and Ischemia Reperfusion Injury treatment guidelines. The assessment part of the report embraces, in depth Ischemia Reperfusion Injury commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ischemia Reperfusion Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Ischemia Reperfusion Injury R&D. The therapies under development are focused on novel approaches to treat/improve Ischemia Reperfusion Injury.
This segment of the Ischemia Reperfusion Injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Treprostinil: United Therapeutics
Treprostinil is a synthetic analogue of prostacyclin. The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects. United Therapeutics is conducting a Phase I/II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation.
Combination of 5-ALA and Sodium Ferrous Citrate: SBI Pharmaceuticals
5-ALA is an amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. In March 2021, SBI Pharmaceuticals and the University of Oxford announced that the University of Oxford has initiated a dose-finding Phase II clinical trial [Pre-operative 5-Aminolevulinic acid to activate haem oxygenase to improve outcomes in cardiac surgery: A dose finding study (Eudra CT Number: TALEN - 2020-001135-27)] (the “Clinical Trial”) to develop a cardioprotective agent combining 5-ALA hydrochloride and Sodium ferrous citrate (iron) for the mitigation of ischemia-reperfusion injury in response to cardiac surgery under cardiopulmonary bypass (CPB) under the terms of the clinical trial sponsorship agreement between the two parties.
This segment of the report provides insights about the different Ischemia Reperfusion Injury drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 18+ key companies which are developing the therapies for Ischemia Reperfusion Injury. The companies which have their Ischemia Reperfusion Injury drug candidates in the most advanced stage, i.e. phase II include, SBI Pharmaceuticals.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ischemia Reperfusion Injury: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ischemia Reperfusion Injury therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ischemia Reperfusion Injury drugs.
Geography Covered
- Global coverage
Ischemia Reperfusion Injury Understanding
Ischemia Reperfusion Injury: Overview
Ischaemia-Reperfusion injury (IRI) is defined as the paradoxical exacerbation of cellular dysfunction and death, following restoration of blood flow to previously ischaemic tissues. Reestablishment of blood flow is essential to salvage ischaemic tissues. However reperfusion itself paradoxically causes further damage, threatening function and viability of the organ. IRI occurs in a wide range of organs including the heart, lung, kidney, gut, skeletal muscle and brain and may involve not only the ischaemic organ itself but may also induce systemic damage to distant organs, potentially leading to multi-system organ failure. Reperfusion injury is a multi-factorial process resulting in extensive tissue destruction.
"Ischemia Reperfusion Injury - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ischemia Reperfusion Injury pipeline landscape is provided which includes the disease overview and Ischemia Reperfusion Injury treatment guidelines. The assessment part of the report embraces, in depth Ischemia Reperfusion Injury commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ischemia Reperfusion Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Ischemia Reperfusion Injury R&D. The therapies under development are focused on novel approaches to treat/improve Ischemia Reperfusion Injury.
Ischemia Reperfusion Injury Emerging Drugs Chapters
This segment of the Ischemia Reperfusion Injury report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ischemia Reperfusion Injury Emerging Drugs
Treprostinil: United Therapeutics
Treprostinil is a synthetic analogue of prostacyclin. The major pharmacological actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In addition to treprostinil's direct vasodilatory effects, it also inhibits inflammatory cytokine. As a synthetic analogue of prostacyclin, it binds to the prostacyclin receptor, which subsequently induces the aforementioned downstream effects. United Therapeutics is conducting a Phase I/II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation.
Combination of 5-ALA and Sodium Ferrous Citrate: SBI Pharmaceuticals
5-ALA is an amino acid produced in mitochondria. It is an important substance that serves as a functional molecule related to energy production in the form of heme and cytochromes, and its productivity is known to decrease with age. In March 2021, SBI Pharmaceuticals and the University of Oxford announced that the University of Oxford has initiated a dose-finding Phase II clinical trial [Pre-operative 5-Aminolevulinic acid to activate haem oxygenase to improve outcomes in cardiac surgery: A dose finding study (Eudra CT Number: TALEN - 2020-001135-27)] (the “Clinical Trial”) to develop a cardioprotective agent combining 5-ALA hydrochloride and Sodium ferrous citrate (iron) for the mitigation of ischemia-reperfusion injury in response to cardiac surgery under cardiopulmonary bypass (CPB) under the terms of the clinical trial sponsorship agreement between the two parties.
Ischemia Reperfusion Injury: Therapeutic Assessment
This segment of the report provides insights about the different Ischemia Reperfusion Injury drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Ischemia Reperfusion Injury
There are approx. 18+ key companies which are developing the therapies for Ischemia Reperfusion Injury. The companies which have their Ischemia Reperfusion Injury drug candidates in the most advanced stage, i.e. phase II include, SBI Pharmaceuticals.
Phases
This report covers around 18+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Ischemia Reperfusion Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ischemia Reperfusion Injury: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ischemia Reperfusion Injury therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ischemia Reperfusion Injury drugs.
Ischemia Reperfusion Injury Report Insights
- Ischemia Reperfusion Injury Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Ischemia Reperfusion Injury Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ischemia Reperfusion Injury drugs?
- How many Ischemia Reperfusion Injury drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ischemia Reperfusion Injury?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ischemia Reperfusion Injury therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ischemia Reperfusion Injury and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- United Therapeutics
- SBI Pharmaceuticals
- Aphios Corporation
- Celdara Medical
- Intercept Pharmaceuticals
- Revive Therapeutics
- Amyndas Pharmaceuticals
- Aptorum Group Ltd
- Argenx
- Balmes Transplantation SAS
- Bolder Bio Technology
- CFM Pharma
- Everon Biosciences
- Gero Discovery
- Glucox Biotech AB
- Ischemix
- Lee's Pharmaceutical Holdings Limited
- LG Chem
- New Horizons Pharma
- Stealth BioTherapeutics
Key Products
- Treprostinil
- Combination of 5-ALA and Sodium Ferrous Citrate
- AH-190P2
- APP-103TM
- INT-767
- Cannabidiol
- MTP-131
- gemigliptin
- NLS-3
- ARGX-117
- CMX-2043
- Anfibatide
- BBT-059
- VANADIS
- Rapatar
Table of Contents
IntroductionExecutive Summary
Ischemia Reperfusion Injury: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Ischemia Reperfusion Injury - Analytical Perspective
Mid Stage Products
- Comparative Analysis
Combination of 5-ALA and Sodium Ferrous Citrate: SBI Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products
- Comparative Analysis
Treprostinil: United Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Ischemia Reperfusion Injury Key Companies
Ischemia Reperfusion Injury Key Products
Ischemia Reperfusion Injury- Unmet Needs
Ischemia Reperfusion Injury- Market Drivers and Barriers
Ischemia Reperfusion Injury- Future Perspectives and Conclusion
Ischemia Reperfusion Injury Analyst Views
Ischemia Reperfusion Injury Key Companies
AppendixList of Tables
Table 1 Total Products for Ischemia Reperfusion Injury
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Ischemia Reperfusion Injury
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Amyndas Pharmaceuticals
- Aphios Corporation
- Aptorum Group Ltd
- Argenx
- Balmes Transplantation SAS
- Bolder Bio Technology
- Celdara Medical
- CFM Pharma
- Everon Biosciences
- Gero Discovery
- Glucox Biotech AB
- Intercept Pharmaceuticals
- Ischemix
- Lee’s Pharmaceutical Holdings Limited
- LG Chem
- New Horizons Pharma
- Revive Therapeutics
- SBI Pharmaceuticals
- Stealth BioTherapeutics
- United Therapeutics
